AI mammography cuts interval cancers by 12%, world-first Lancet study shows
AI-backed mammography screening led to 27% fewer non-luminal A subtype interval cancers and 21% fewer large tumours.
AI-assisted mammography screening reduces interval cancers by 12% compared with standard screening, according to final results from a world-first trial.
The Mammography Screening with AI trial, which was embedded within Sweden’s national breast screening program, involved 105,934 women aged 40 to 74.
For about 53,000 women, a commercially available AI scored their mammograms from 1 to 10 for cancer risk.
Those ranked 1-9 went to a single radiologist reading while those ranked 10 went to a double reading.
